EMA Authorised: Relistor (methylnaltrexone bromide) — Bausch Health Ireland Limited

View source ↗

Summary

The EMA authorised Relistor (methylnaltrexone bromide) by Bausch Health Ireland Limited for opioid-induced constipation. The decision date was 19 January 2026.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid-induced Constipation

Drugs mentioned

• RELISTOR (methylnaltrexone)

Snippet

Status: Authorised. Therapeutic area: Opioid-Related Disorders;Constipation. MAH: Bausch Health Ireland Limited. Decision date: 19/01/2026